Impact Trial Data Shows Clear Benefit In Using Roche S Cintec Plus Bioreference will offer the test to women from ages 30 to 65 as a reflex when the cytology result is negative for intraepithelial lesion or malignancy (nilm) and the high risk hpv result is positive using roche’s cobas hpv test. the dual stain biomarker test allows a treating healthcare provider to more accurately and quickly assess the risk. Bioreference® health llc, one of the largest full service specialty laboratories in the united states, announced today it will be one of the first commercial laboratories to use offer the cintec® plus cytology test from roche diagnostics. cintec plus cytology is the only fda approved dual stain triage test for patients who have a high risk.
Bioreference Offering Roche Diagnostics Cytology Test For Women At High When detected at an early stage, the five year survival rate for women with invasive cervical cancer is 92%. 1 in the impact clinical trial, testing with cintec plus cytology as a triage detected cervical disease earlier than pap cytology in seven out of 10 women who were already identified as hpv positive. 2,3 the biomarker based cintec plus cytology test showed a significantly higher. Bioreference will offer the test to women aged 30 65 as a reflex when the cytology result is nilm and the hrhpv result is positive with cobas ® hpv test. the dual stain biomarker test allows a. Roche's cervical cancer portfolio includes the cobas hpv test, used for primary screening and co testing, which tests for 14 types of high risk hpv genotypes in cervical cancer. Cintec® plus cytology offered as a reflex test when cytology is nilm and hpv positiveelmwood park, n.j., feb. 9, 2023 prnewswire bioreference.
Comments are closed.